Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Value-Based Pricing: Do Not Throw Away the Baby with the Bath Water.

Neyt M.

Pharmacoeconomics. 2017 Oct 3. doi: 10.1007/s40273-017-0566-5. [Epub ahead of print] No abstract available.

PMID:
28975551
2.

CARDIOVASCULAR SCREENING OF YOUNG ATHLETES: A REVIEW OF ECONOMIC EVALUATIONS.

Gerkens S, Van Brabandt H, Desomer A, Leonard C, Neyt M.

Int J Technol Assess Health Care. 2017 Jan;33(1):76-83. doi: 10.1017/S0266462317000162. Epub 2017 Apr 24.

PMID:
28436336
3.

Introduction of high-risk medical devices: national measures that can be taken under the current European legislation to put the patient interest central.

Neyt M, Baeyens H, Pouppez C, Slegers P, Hulstaert F, Stordeur S, Vinck I.

Expert Rev Med Devices. 2017 Mar;14(3):181-188. doi: 10.1080/17434440.2017.1288095. Epub 2017 Feb 4.

PMID:
28128008
4.

Publicly funded practice-oriented clinical trials: of importance for healthcare payers.

Neyt M, Christiaens T, Demotes J, Walley T, Hulstaert F.

J Comp Eff Res. 2016 Nov;5(6):551-560. Epub 2016 Sep 5.

PMID:
27595308
5.

Analysis authors reply to Response by Corrado and colleagues.

Van Brabandt H, Desomer A, Gerkens S, Neyt M.

BMJ. 2016 Aug 23;354:i4509. doi: 10.1136/bmj.i4509. No abstract available.

PMID:
27554861
6.

Harms and benefits of screening young people to prevent sudden cardiac death.

Van Brabandt H, Desomer A, Gerkens S, Neyt M.

BMJ. 2016 Apr 20;353:i1156. doi: 10.1136/bmj.i1156. Review. No abstract available.

PMID:
27097983
7.

Contingent non-invasive prenatal testing: an opportunity to improve non-genetic aspects of fetal aneuploidy screening.

Gyselaers W, Hulstaert F, Neyt M.

Prenat Diagn. 2015 Dec;35(13):1347-52. doi: 10.1002/pd.4704. Epub 2015 Oct 27.

PMID:
26443424
8.

Which quality of life measures fit your relative effectiveness assessment?

Cleemput I, Neyt M.

Int J Technol Assess Health Care. 2015 Jan;31(3):147-53. doi: 10.1017/S0266462315000215. Epub 2015 Jun 11.

PMID:
26062796
9.

Belgian guidelines for economic evaluations: second edition.

Thiry N, Neyt M, Van De Sande S, Cleemput I.

Int J Technol Assess Health Care. 2014 Dec;30(6):601-7. doi: 10.1017/S0266462314000725.

PMID:
25816826
10.

Endpoints for relative effectiveness assessment (REA) of pharmaceuticals.

Pavlovic M, Teljeur C, Wieseler B, Klemp M, Cleemput I, Neyt M.

Int J Technol Assess Health Care. 2014 Nov;30(5):508-13. doi: 10.1017/S0266462314000592.

PMID:
25747560
11.

Belgian guidelines for budget impact analyses.

Neyt M, Cleemput I, Sande SV, Thiry N; Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium.

Acta Clin Belg. 2015 Jun;70(3):175-80. doi: 10.1179/2295333714Y.0000000118. Epub 2015 Jan 11.

PMID:
25579611
12.

The cost-utility of left ventricular assist devices for end-stage heart failure patients ineligible for cardiac transplantation: a systematic review and critical appraisal of economic evaluations.

Neyt M, Van den Bruel A, Smit Y, De Jonge N, Vlayen J.

Ann Cardiothorac Surg. 2014 Sep;3(5):439-49. doi: 10.3978/j.issn.2225-319X.2014.09.02. Review.

13.

Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis.

Neyt M, Hulstaert F, Gyselaers W.

BMJ Open. 2014 Nov 7;4(11):e005922. doi: 10.1136/bmjopen-2014-005922.

14.

Search MEDLINE for economic evaluations: tips to translate an OVID strategy into a PubMed one.

Neyt M, Chalon PX.

Pharmacoeconomics. 2013 Dec;31(12):1087-90. doi: 10.1007/s40273-013-0103-0. No abstract available.

PMID:
24202991
15.

Authors' reply to Ward.

Van Brabandt H, Neyt M, Devos C.

BMJ. 2013 Oct 2;347:f5868. doi: 10.1136/bmj.f5868. No abstract available.

PMID:
24088554
16.

The cost-utility of catheter ablation of atrial fibrillation: a systematic review and critical appraisal of economic evaluations.

Neyt M, Van Brabandt H, Devos C.

BMC Cardiovasc Disord. 2013 Sep 26;13:78. doi: 10.1186/1471-2261-13-78. Review.

17.

Caution over use of catheter ablation for atrial fibrillation.

Van Brabandt H, Neyt M, Devos C.

BMJ. 2013 Sep 6;347:f5277. doi: 10.1136/bmj.f5277. No abstract available. Erratum in: BMJ. 2013;347:f5688.

PMID:
24014443
18.

Cost-effectiveness of continuous-flow left ventricular assist devices.

Neyt M, Van den Bruel A, Smit Y, De Jonge N, Erasmus M, Van Dijk D, Vlayen J.

Int J Technol Assess Health Care. 2013 Jul;29(3):254-60. doi: 10.1017/S0266462313000238. Epub 2013 Jun 14.

PMID:
23763844
19.

Health technology assessment on catheter ablation of atrial fibrillation in Belgium.

Van Brabandt H, Neyt M, Devos C.

Europace. 2013 May;15(5):618-9. doi: 10.1093/europace/eut085. No abstract available.

PMID:
23625940
20.

[Introduction of innovative high-risk medical devices in Europe: are clinical efficacy and safety guaranteed?].

Stordeur S, Vinck I, Neyt M, Van Brabandt H, Hulstaert F.

Rev Epidemiol Sante Publique. 2013 Apr;61(2):105-10. doi: 10.1016/j.respe.2012.08.004. Epub 2013 Mar 7. French.

PMID:
23477881

Supplemental Content

Support Center